Article
Infectious Diseases
Cindy Lau, Deborah Marriott, Jessica Bui, Melanie Figtree, Michael Gould, Adriana Chubaty, Yuen Su, Suman Adhikari, Pam Konecny, Kristi Kozierowski, Taylor Holland, Eliza Milliken, Ayesha Akram, Alexander Mcnamara, Yihui Sun, Sebastiaan Van Hal, Asad E. Patanwala, Aryan Shahabi-Sirjani, Timothy Gray, Chin Yen Yeo, Angela Netluch, Stephanie Halena, Marcelle Appay, Rozanna Alameddine, Fiona Yin, Quoc Nguyen, Mei-Yi So, Indy Sandaradura, Hannah Yejin Kim, Semun Galimam, Nicole Cerruto, Tony Lai, Timothy Gilbey, Kathryn Daveson, Stephanie E. Reuter, Jonathan Penm, Jan-Willem Alffenaar
Summary: This study aimed to evaluate linezolid toxicity in a large multicentre cohort and found that linezolid treatment-limiting toxicity remains a problem. TDM-guided dose optimisation significantly reduced the risk of toxicity and a treatment duration beyond 28 days was no longer significantly associated with toxicity.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Public, Environmental & Occupational Health
Bin Lin, Yangmin Hu, Ping Xu, Tao Xu, Chunyan Chen, Le He, Mi Zhou, Zhangzhang Chen, Chunhong Zhang, Xuben Yu, Luo Fang, Junfeng Zhu, Yanlan Ji, Qun Lin, Hengbin Cao, Youqin Dai, Xiaoyan Lu, Changcheng Shi, Li Li, Changjiang Wang, Xumei Li, Qiongyan Fang, Jing Miao, Zhengyi Zhu, Guangyong Lin, Haichao Zhan, Shiwen Lv, Yalan Zhu, Xinjun Cai, Yin Ying, Meng Chen, Qiong Xu, Yiwen Zhang, Yubin Xu, Pea Federico, Saiping Jiang, Haibin Dai
Summary: Through in-depth research on Linezolid, a team of experts from various disciplines has formed a consensus on the therapeutic drug monitoring and safe use of Linezolid.
FRONTIERS IN PUBLIC HEALTH
(2022)
Review
Cell Biology
He Liu, Zhen Hu, Mengyang Li, Yi Yang, Shuguang Lu, Xiancai Rao
Summary: G(+) bacterial infections pose a significant burden and require urgent development of antimicrobial agents due to the prevalence of multidrug-resistant G(+) bacteria. Endolysins, phage-encoded enzymes, are promising alternatives for combating resistance due to their low bacterial resistance. This review classifies and summarizes the mechanisms, efficacy, and advantages of endolysins as antibacterial drug candidates targeting G(+) bacteria. Safety, challenges, and potential solutions are also addressed, with indications that endolysin-based drugs will be approved in the near future.
JOURNAL OF BIOMEDICAL SCIENCE
(2023)
Article
Pharmacology & Pharmacy
Ying Dai, Shuying Jiang, Xiaoou Chen, Lu Han, Chunhong Zhang, Xuben Yu, Xiuhua Zhang
Summary: Hepatic and/or renal dysfunction were identified as the risk factors for LZD-induced haematological toxicity, while maintaining the target plasma trough concentration within 8 mg/L through dose reduction could minimize the haematological toxicity induced by LZD.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2021)
Article
Chemistry, Multidisciplinary
Musaed Alkholief, Mohd Abul Kalam, Abdullah K. Alshememry, Raisuddin Ali, Sulaiman S. Alhudaithi, Nasser B. Alsaleh, Mohammad Raish, Aws Alshamsan
Summary: Linezolid-loaded chitosan nanoparticles were developed for the topical treatment of bacterial eye infections. The nanoparticles showed sustained drug release and enhanced antibacterial activity compared to the free drug.
Article
Infectious Diseases
Georgia Loane, Amanda Gwee
Summary: The majority of noncritically ill children receiving teicoplanin had drug levels within the therapeutic range, and most children with Gram-positive infections achieved cure.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY
(2021)
Article
Medicine, General & Internal
Qian Wu, Xiaohua Xu, Mingqing Tian, Jianyang Jiang
Summary: This systematic review and meta-analysis compared the efficacy and safety of linezolid and vancomycin for treating resistant Gram-positive bacterial infections in children under 12 years. The findings showed that linezolid and vancomycin had similar clinical cure rates and pathogen eradication rates, but linezolid had better safety profile than vancomycin.
Article
Infectious Diseases
Yongli Wei, He Zhang, Maowu Fu, Rui Ma, Ronghui Li, Lingti Kong
Summary: This study aimed to analyze the pharmacokinetics/pharmacodynamics (PK/PD) of linezolid in patients with intracerebral hemorrhage and provide recommendations for dosing and treatment regimens. The study found that linezolid had high target attainment probability (PTA) in plasma and sputum when the minimum inhibitory concentration (MIC) was <= 1 mg/L. Linezolid showed the highest cumulative fraction of response (CFR) against Streptococcus pneumoniae, followed by Enterococcus faecalis and Enterococcus faecium, with the lowest value for MRSA. This study provides valuable insights for selecting appropriate dosing regimens for linezolid in patients with intracerebral hemorrhage.
INFECTION AND DRUG RESISTANCE
(2022)
Article
Infectious Diseases
Hannah Yejin Kim, Evelien Ruiter, Erwin M. Jongedijk, Hemanth Kumar Ak, Ben J. Marais, P. K. Bhavani, Shailendra Sawleshwarkar, Daan J. Touw, Jan-Willem Alffenaar
Summary: The study validated the feasibility and accuracy of a UV spectrophotometric assay using non-invasive saliva sampling for linezolid.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Review
Infectious Diseases
Carolina Osorio, Laura Garzon, Diego Jaimes, Edwin Silva, Rosa-Helena Bustos
Summary: Antimicrobial resistance is a threatening problem for antibiotic therapy, and therapeutic drug monitoring, particularly for drugs like daptomycin, is crucial for improving treatment outcomes and combating resistance.
Article
Infectious Diseases
Christophe Marti, Pierre Lescuyer, David Tonoli, Elodie von Dach, Angela Huttner
Summary: Therapeutic drug monitoring (TDM) of amoxicillin is important for overcoming antimicrobial resistance. This study aimed to define target amoxicillin plasma concentrations and assess their association with clinical outcomes. Results showed significant variations in amoxicillin concentrations, but low trough levels did not correlate with clinical failure. Although no toxicity threshold was established, patients with the highest trough concentrations did not experience increased adverse events, suggesting that trough levels up to 40 mg/L may be safe.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2022)
Article
Infectious Diseases
Altea Gallerani, Milo Gatti, Andrea Bedini, Stefania Casolari, Gabriella Orlando, Cinzia Puzzolante, Erica Franceschini, Marianna Menozzi, Antonella Santoro, Nicole Barp, Sara Volpi, Alessandra Soffritti, Federico Pea, Cristina Mussini, Marianna Meschiari
Summary: This retrospective case series reports on the use of dalbavancin in the treatment of cardiovascular prosthetic infections. The results show that dalbavancin is effective and well-tolerated in this setting. Monitoring drug concentrations can individualize dosing and dosing intervals, further improving clinical outcomes.
Article
Pharmacology & Pharmacy
Zaiwei Song, Lan Ma, Li Bao, Yi Ma, Ping Yang, Dan Jiang, Aijun Liu, Lu Zhang, Yan Li, Yinchu Cheng, Fei Dong, Rongsheng Zhao, Hongmei Jing
Summary: In this study, the exposure-safety relationship of lenalidomide (LEN) was evaluated, and a target concentration for toxicity was determined. Monitoring the concentration of LEN can improve medication safety and ensure continuous treatment for patients with multiple myeloma and non-Hodgkin lymphoma.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Satish Bhawsar, Shivaji Pawar, Prasad Deshpande, Ravindra Yeole, Rajesh Chavan, Manohar Nandanwar, Sachin Bhagwat, Mahesh Patel
Summary: The oxazolidinone antibiotic WCK 4034, synthesized through a structure activity relationship (SAR) program, has shown competitive activity against gram positive infections and superior pharmacokinetic properties compared to Linezolid. It has successfully completed pre-clinical studies and is ready for clinical development, paving the way for the development of other oxazolidinone NCEs.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2022)
Review
Infectious Diseases
Sharon Lechtig-Wasserman, Hans Liebisch-Rey, Nicolas Diaz-Pinilla, Jhosep Blanco, Yuli-Viviana Fuentes-Barreiro, Rosa-Helena Bustos
Summary: This paper investigates the effectiveness of therapeutic drug monitoring (TDM) in critically ill patients treated with carbapenems, finding a potential relationship with clinical cure and target attainment but no clear association with decreased mortality. Studies also suggest some favorable outcomes in terms of clinical and microbiological responses compared to standard care, though strong evidence was not identified due to limitations in study size, bias risk, and design.
Review
Infectious Diseases
Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman
Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2024)
Article
Infectious Diseases
Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri
Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2024)